DELSITECH OY

Their core work

DELSITECH OY is a Finnish private company specializing in mesoporous carrier materials engineered for controlled, site-specific drug delivery. Their core technology involves designing porous matrices that release therapeutic ions and pharmaceutical compounds in response to pH changes — enabling localized treatment where conventional delivery methods fall short. In the MOZART project they contributed as an industry participant to developing these smart material systems, and through the OcuTher training network they engage with the ocular drug delivery scientific community as a third-party industrial partner. They function as a commercial bridge between nanomaterials research and pharmaceutical application development.

What they specialise in

How they've shifted over time

With only two projects running in near-parallel timeframes (MOZART 2015-2019, OcuTher 2016-2020), there is no meaningful chronological separation to trace a shift in focus. Both projects address drug delivery from complementary angles: MOZART from a materials science and fabrication perspective, OcuTher from a therapeutic application and research training angle. No keywords were available in the CORDIS data to support vocabulary evolution analysis, so the profile appears stable and tightly focused rather than evolving across the H2020 period.

DELSITECH's dual presence in a nanotechnology RIA and a Marie Curie training network suggests a company simultaneously building technical credibility and scientific network depth, likely positioning for pharma or medical device industry partnerships in the precision drug delivery space.

How they like to work

DELSITECH has never served as a project coordinator, joining consortia as a participant or third-party contributor — consistent with a specialist technology provider that brings a specific material capability rather than driving project agendas. Despite only two projects, they connected with 26 partners across 12 countries, indicating participation in large, geographically distributed consortia. Working with them means gaining focused industrial expertise in porous delivery materials without expecting project management leadership from their side.

DELSITECH reached 26 unique consortium partners across 12 countries through just two projects, reflecting involvement in broad European research networks spanning both nanotechnology and pharmaceutical training consortia. Their Turku base combined with this wide European reach is typical of Finnish industrial players active in EU-funded research programs.

What sets them apart

As a private Finnish company — not a university or research institute — DELSITECH brings commercially-oriented expertise in mesoporous carrier materials to academically-led consortia, a profile that is uncommon in this niche. Their specific focus on pH-responsive, localized release systems distinguishes them from generalist materials suppliers and from academic groups lacking product-development orientation. For consortium builders, they offer proprietary industrial material technology at a research-ready stage, filling the industry partner slot with genuinely relevant technical substance.

Highlights from their portfolio

• MOZART
  Their only directly funded H2020 project (EUR 225,000), and the clearest evidence of their core competency: engineering mesoporous matrices that release therapeutic ions and drugs in response to pH — a precision delivery challenge with significant clinical relevance.
• OcuTher
  Participation as a third party in a Marie Curie Innovative Training Network on ocular drug delivery shows engagement with the research training community, extending their network beyond pure technology consortia into academic education programs focused on ophthalmic therapeutics.